Furthermore, it was reported that CDC20 overexpression facilitates the docetaxel resistance of the castration-resistant prostate cancer (CRPC) cell lines in a Bim-dependent manner, indicating that the drugs targeting CDC20 were urgent to be developed for the treatment of the CRPC with docetaxel resistance (Wu et al., 2018). Here, CDC20 is linked to prostate carcinoma.